Adjuvant Capital Management, LLC
SEC CIK 1935084 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc. | 10% | 377.5K | — | $1.99M | 4 | 2023-11-14 | 2024-01-16 |
Most active insiders at ANTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Readnour Robin Shane | Dir | — | $316.7K |
| 2 | Eizen Joshua M | See Remarks | — | $52.9K |
| 3 | FitzPatrick Margaret M | Dir | $11.6K | — |
| 4 | Chanda Sanjay | Chief Development Off | — | $9,311 |
| 5 | Day Lucy | CFO | — | $8,862 |
| 6 | Prior Stephen David | Chief Strategy Off | — | $7,363 |
| 7 | Williams Sarah Joanne | Principal Accounting Off | — | $3,025 |
| 8 | Trenor Cameron C. III | Chief Medical Off | — | — |
| 9 | Marks Gilbert Lynn | Dir | — | — |
| 10 | Martin Patricia A. | Dir | — | — |
Adjuvant Capital Management, LLC made no open-market trades at ANTX in the last 12 months.
Transactions 4
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-01-18 | 2024-01-16 | ANTX | AN2 Therapeutics, Inc. | Adjuvant Capital Management, LLC | 10% | S - Sale | $19.65 | -15.9K | 377.5K | -4% | -$312.6K |
| 2024-01-18 | 2024-01-16 | ANTX | AN2 Therapeutics, Inc. | Adjuvant Capital Management, LLC | 10% | S - Sale | $19.65 | -84.1K | 2.00M | -4% | -$1.65M | |
| TI | 2023-11-16 | 2023-11-14 | ANTX | AN2 Therapeutics, Inc. | Adjuvant Capital Management, LLC | 10% | S - Sale | $16.15 | -288 | 393.4K | -0.1% | -$4,651 |
| T | 2023-11-16 | 2023-11-14 | ANTX | AN2 Therapeutics, Inc. | Adjuvant Capital Management, LLC | 10% | S - Sale | $16.15 | -1,522 | 2.08M | -0.1% | -$24.6K |
Purchase Sale Sale after option exercise All abbreviations